Transferred from: Medicilon

On November 22, sponsored by China Times, the "New Quality Productivity Leads Change· AI Technology Empowers Innovation and Development" The 4th China Health Industry Development Conference and Golden Cane Award Ceremony was successfully held in Beijing. At the conference, the winners of the 4th Golden Cane Award were officially announced!

Shanghai Medicilon Biopharmaceutical Co., Ltd. (hereinafter referred to as "Medicilon") won the Golden Cane Award of "Top Ten Innovative Biotechnology Enterprises in 2024" for its innovative practice in the field of artificial intelligence AI + pharmaceutical.

About the Golden Cane Award

The Golden Cane Award is a health industry award launched by China Times based on the platform of the China Health Industry Development Conference, aiming to recognize the most powerful and innovative enterprises, brands and products in the fields of medicine, medical treatment and health of the year. The award has become one of the most influential selections in the industry, and has been actively participated and highly praised by many enterprises, and is known as the "Oscar of Human Health".

Medicilon: AI empowers the research and development of new drugs, and CRO services are further upgraded

In the context of the era of new quality productivity leading change, AI technology is empowering all walks of life at an unprecedented speed, and the biomedical field is benefiting a lot. Medicilon actively responded to the call of the times, took the lead in deeply integrating AI technology into the new drug R&D process, and built an AI drug discovery service platform. Through efficient computing and data analysis capabilities, the platform can provide researchers with a full range of technical support from protein structure prediction and simulation, binding site discovery, information extraction and cleaning, and customized project database construction, helping to improve R&D efficiency and reduce R&D costs.

It is worth mentioning that Medicilon, relying on a one-stop preclinical preclinical R&D service platform, has reached strategic cooperation with AI companies such as Insilico Medicine and Dray, and has provided a full set of preclinical R&D services including pharmacokinetics and safety evaluation for Insilico Medicine's ISM3412 drugs. Provided API process development and formulation development services for MDR-001 of Derva Medicine, and jointly promoted the rapid clinical approval of the drug. This cross-border cooperation not only accelerates the process of new drug research and development, but also sets a model for the industry to empower new drug research and development with AI.

Winning the Golden Cane Award of "Top Ten Innovative Biotechnology Enterprises in 2024" is not only an affirmation of Medicilon's past achievements in AI-enabled new drug research and development, but also an incentive for continuous innovation in the future. Medicilon will continue to uphold the spirit of innovation, deepen collaboration with global partners, jointly lead the change with new quality productivity, empower innovation and development with AI technology, and contribute more wisdom and strength to the development of the biomedical industry.

Preview of the live stream

Medicilon (stock code: 688202.HK) Founded in 2004 and headquartered in Shanghai, SH is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and researchers. Medicilon's one-stop comprehensive service helps customers accelerate the process of new drug development with strong project management and more efficient and cost-effective R&D services, covering the whole process of pharmaceutical preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research. By the end of June 2024, Medicilon has provided drug R&D services to more than 2,000 customers around the world, and has participated in the research and development of 490 IND approved clinical trials of new drugs and generic drugs, growing together with high-quality customers at home and abroad. Medicilon will continue to be based on a global vision, focus on China's innovation, and contribute to human health!

(Redirected from: Medicilon).